Omeros
As of the edition of 20 October 2026, Omeros runs 7 drugs, 1 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 4 |
| Stopped | 1 |
| Total | 7 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Narsoplimab | Ends 2037 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| MASP2 Mannan-binding lectin serine protease 2 | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Omeros needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Blood and lymph: 6 trials led
- Eye: 6 trials led
- Pregnancy and women's health: 6 trials led